Matches in Wikidata for { <http://www.wikidata.org/entity/Q61684784> ?p ?o ?g. }
Showing items 1 to 55 of
55
with 100 items per page.
- Q61684784 description "2012 թվականի հունիսի 12-ին հրատարակված գիտական հոդված" @default.
- Q61684784 description "artículu científicu espublizáu en xunu de 2012" @default.
- Q61684784 description "im Juni 2012 veröffentlichter wissenschaftlicher Artikel" @default.
- Q61684784 description "scientific article published on 12 June 2012" @default.
- Q61684784 description "wetenschappelijk artikel" @default.
- Q61684784 description "наукова стаття, опублікована в червні 2012" @default.
- Q61684784 name "Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extensi" @default.
- Q61684784 name "Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extensi" @default.
- Q61684784 type Item @default.
- Q61684784 label "Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extensi" @default.
- Q61684784 label "Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extensi" @default.
- Q61684784 prefLabel "Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extensi" @default.
- Q61684784 prefLabel "Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extensi" @default.
- Q61684784 P1433 Q61684784-703CA65F-AD0A-429B-BF57-DB8BDD928D23 @default.
- Q61684784 P1476 Q61684784-C91C6A56-2621-486E-B670-0D7E6CB85802 @default.
- Q61684784 P2093 Q61684784-1D13802B-7398-4D90-842A-0ADCFE5AF5E8 @default.
- Q61684784 P2093 Q61684784-5D0926A8-7C40-411A-8430-38BD5E6254FA @default.
- Q61684784 P2093 Q61684784-5D5B78A6-C020-4402-985E-8FF64214C385 @default.
- Q61684784 P2093 Q61684784-83999170-0BA2-41FF-8AA8-63F98A07A507 @default.
- Q61684784 P2093 Q61684784-87EA5FEE-492D-49A2-BD39-F83722E0AEEB @default.
- Q61684784 P2093 Q61684784-B023EE2E-37AB-4AEF-A8AA-079B2160F996 @default.
- Q61684784 P304 Q61684784-35A0BAF2-F2A6-4435-8385-DAAAF5F537E1 @default.
- Q61684784 P31 Q61684784-836F2EB3-E552-489B-890E-5EB2FD07BAA7 @default.
- Q61684784 P356 Q61684784-A17EE3B8-13F0-4CFF-B6C2-469420A4AF78 @default.
- Q61684784 P433 Q61684784-284EEAF1-5725-4863-B899-6F00707DD984 @default.
- Q61684784 P478 Q61684784-CFE07E63-DD77-44B4-A931-C42A14A99C5B @default.
- Q61684784 P50 Q61684784-0BC90363-3870-4ACF-B9F9-C84993D6DA95 @default.
- Q61684784 P50 Q61684784-B877C7C6-93A1-4D82-AB34-0442F0F03EFE @default.
- Q61684784 P577 Q61684784-21C25C5C-2758-4784-8135-4FB9B14BD202 @default.
- Q61684784 P698 Q61684784-3AEC094D-3583-4D00-9208-EB04AAB9555D @default.
- Q61684784 P921 Q61684784-4F81340E-CBBC-48CD-BBBB-E3974CD76565 @default.
- Q61684784 P921 Q61684784-70714DFD-699B-412D-AACF-5E6F54E8D52F @default.
- Q61684784 P921 Q61684784-A537BC6E-536D-46F1-8AE2-29D65E9A6C38 @default.
- Q61684784 P356 J.1742-1241.2012.02975.X @default.
- Q61684784 P698 22691164 @default.
- Q61684784 P1433 Q15758177 @default.
- Q61684784 P1476 "Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extension" @default.
- Q61684784 P2093 "A Pivovarova" @default.
- Q61684784 P2093 "A Schlosser" @default.
- Q61684784 P2093 "D R Owens" @default.
- Q61684784 P2093 "H-J Woerle" @default.
- Q61684784 P2093 "R Gomis" @default.
- Q61684784 P2093 "S Patel" @default.
- Q61684784 P304 "731-740" @default.
- Q61684784 P31 Q13442814 @default.
- Q61684784 P356 "10.1111/J.1742-1241.2012.02975.X" @default.
- Q61684784 P433 "8" @default.
- Q61684784 P478 "66" @default.
- Q61684784 P50 Q18246437 @default.
- Q61684784 P50 Q41467287 @default.
- Q61684784 P577 "2012-06-12T00:00:00Z" @default.
- Q61684784 P698 "22691164" @default.
- Q61684784 P921 Q3025883 @default.
- Q61684784 P921 Q42824827 @default.
- Q61684784 P921 Q909745 @default.